The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VXRT | -39.34% | -94.74% | -44.47% | -96% |
| S&P | +14.18% | +88.25% | +13.47% | +154% |
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.
Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $72.41M | 1367.9% |
| Gross Profit | $70.33M | 1734.9% |
| Gross Margin | 97.13% | 19.4% |
| Market Cap | $83.52M | -56.7% |
| Market Cap / Employee | $0.73M | 0.0% |
| Employees | 115 | -8.0% |
| Net Income | -$8.14M | 42.2% |
| EBITDA | -$5.73M | 57.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $16.88M | -23.4% |
| Accounts Receivable | $85.95M | 2238.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $12.44M | -28.7% |
| Short Term Debt | $6.52M | 15.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.99% | 26.1% |
| Return On Invested Capital | -66.20% | -4.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $2.48M | 158.9% |
| Operating Free Cash Flow | $2.60M | 161.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.20 | 1.57 | 2.26 | 2.54 | 5.26% |
| Price to Sales | 5.25 | 1.96 | 1.28 | 0.56 | -95.11% |
| Price to Tangible Book Value | 2.50 | 1.82 | 2.73 | 3.32 | 22.97% |
| Enterprise Value to EBITDA | -11.78 | -5.16 | -7.74 | -12.86 | 9.21% |
| Return on Equity | -114.7% | -114.7% | -100.3% | -106.5% | 3.05% |
| Total Debt | $23.28M | $20.56M | $19.02M | $18.96M | -17.85% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
